NTRA Natera Inc
Company Analysis
Latest News
Natera Smashes Q2 Estimates and Lifts Guidance, but Can a Still-Unprofitable Testing Company Justify a $39 Billion Valuation?
Shares of genetic testing company Natera surged 15.3% to $306.01, blasting past the stock's prior 52-week high, after the company delivered a second quarter...
🟢 Natera is trading 21% up today after Q2 revenue beat, raised 2026 guidance
Natera is trading 21% up at $321.21 after reporting $752.8 million in second-quarter revenue, well above expectations, and narrowing its loss to $0.47 per...
🟢 Natera is trading 19% up today after Q2 revenue beat and guidance raise
Natera is trading 19.18% up now at $317.36 after its August 6, 2026 earnings release showed strong second-quarter results and management raised full-year...
🟢 Natera is trading 12.30% up in pre-market after Q2 earnings beat and raised 2026 guidance
Natera is trading at $298.01 (+12.30%) after a Q2 earnings beat that included $752.8 million in revenue, up 37.7% year over year. - Management raised 2026...
🟢 Natera is trading 15.3% up in after-hours trading after Q2 revenue beat and raised 2026 guidance
Natera is trading +15.31% at $306.01 in after-hours trading after reporting Q2 revenue above estimates and raising 2026 revenue guidance. • Q2 revenue reached...
Natera's second quarter 2026 revenue of $753M beat estimates while full-year guidance was raised
Natera reported second quarter 2026 revenue of $752.8 million, up 37.7% year-over-year, and a narrower-than-expected net loss of $67.0 million. The company...
Natera Inc Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Analysts expect Natera to report Q2 2026 revenue of $661.26 million and an EPS loss of $0.49, with the stock currently trading at $270.36, slightly above the...
🟢 Natera is trading 4.8% up today amid broad market gains following cooling inflation data
Natera is trading at $265.80 (+4.78%) as the stock climbs alongside a broader market rally driven by cooling inflation data and positive tech earnings. • The...
🟢 Natera is trading 4.6% up today following a broad risk-on move in U.S. futures
Natera is trading at $274.04 (+4.60%) in pre-market action, driven by a broad risk-on sentiment across U.S. equity markets. • The move aligns with a wider...
Natera Signatera outperforms standard test for skin cancer recurrence, JAMA study shows
Natera published a study in JAMA Dermatology evaluating its Signatera molecular residual disease (MRD) test. The research focused on predicting recurrence in...
🔴 Natera is trading 4% down today amidst ongoing insider selling concerns
Natera is trading at $270.56 (-4.00%) today, as concerns over a recent surge in insider selling activity appear to be weighing on investor sentiment. • Reports...
Natera dominates cancer recurrence market, wins landmark FDA diagnostic approval
Natera holds a near-monopoly in the minimal residual disease (MRD) testing market. The Austin-based company's flagship product, Signatera, detects cancer...
Natera leads cancer recurrence market, holding 80% share with Signatera
Natera Inc. holds an estimated 80% market share in the minimal residual disease (MRD) testing market. The company’s flagship Signatera product uses...
Natera's first quarter 2026 revenue beat estimates by 33% on strong volume growth, prompting a raised full-year outlook.
Natera reported first quarter 2026 revenue of $696.6 million, a 38.8% increase year-over-year, and a net loss per share of ($0.60). The company processed over...
Natera Inc Q1 2026 Earnings Preview: What Analysts Expect on May 07, 2026
For the first quarter of 2026, analysts expect Natera to deliver consensus revenue of $522.5 million and an EPS of -$0.53, with the stock currently trading at...
Natera Inc Q4 2025 Earnings Preview: What Analysts Expect on March 04, 2026
Analysts expect Natera to report Q4 2025 revenue of approximately $600.7 million and an EPS loss of $0.50, with the stock currently trading near $200 compared...
Natera's fourth quarter 2025 revenue beat estimates, driven by 55% growth in oncology test volume.
Natera reported fourth quarter 2025 revenue of $665.5 million, an increase of 39.8% year-over-year, driven by record test volumes and improvements in average...
Natera Inc Reports Q4 2025 Earnings on February 26, 2026
Wall Street expects Natera to report Q4 2025 revenue of approximately $660.45 million and a loss per share of $0.46, with the stock currently trading at...